Faculty from The Ohio State University (OSU) are integrated into the scientific and administrative activities, participate in meetings, manage multiple core labs, design studies and enroll patients in all existing adult NCTN network groups using cancer center resources to leverage group resources. OSU investigators develop and lead studies designed to enroll patients on multi-disciplinary treatment trials as well as develop and perform correlative science related research studies, bringing special expertise in hematologic malignancies and solid tumors. Our medical, hematologic, surgical and radiation oncologists, trans planters, psychiatrists, pathologists, cytogeneticists, translational and basic laboratory scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research coordinators help to frame the clinical and basic science questions whose answers contribute to improved patient outcomes and to understanding tumor biology. The goal of this application is to provide the infrastructure to support OSU's participation in the scientific and clinical research activities of the NCI's NCTN Program as a Network Lead Academic Participating Site (NLAPS). We will use the support to make scientific discoveries about tumor biology, find better treatments and augment the quality of life for patients thus improving outcomes across the spectrum of cancers affecting adults. This comprehensive program aims to: 1) Investigate new therapeutic agents, and their toxicities in Phase I to 1 clinical trials;2) Evaluate the efficacy nd toxicity of novel combinations based on preclinical data to exploit synergistic combinations more effectively;3) Develop multi-modal approaches using surgical, immunological, and radio therapeutic measures in optimal combinations;4) Integrate experts in molecular genetics, biochemistry, pharmacology, immunology, and biostatistics in the design and execution of therapeutic protocols;5) Improve cancer outcomes through discovery and education of pre and post-doctoral students, nurses, allied medical personnel and physicians, 6) Understand and exploit tumor heterogeneity to fully exploit the value of targeted therapies, 7) Improve the management of cancer related symptoms, and 8) enroll patients on trials.
This grant supports OSUCCC's participation in the NCI's sponsored National Cooperative Clinical Trials Network in order to improve the prevention of cancer, better the treatment, and boost the cure rates of adults with cancer. OSUCCC has one of the largest volume academic cancer centers in the US and is fully engaged in NCTN research with each of the existing NCI supported cooperative groups.
|Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442|
|Papaioannou, Dimitrios; Shen, Changxian; Nicolet, Deedra et al. (2017) Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proc Natl Acad Sci U S A 114:E4641-E4647|
|Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2017) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int :|
|Fuchs, Charles S; Niedzwiecki, Donna; Mamon, Harvey J et al. (2017) Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol 35:3671-3677|
|Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340|
|Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892|
|Smith, E M L; Pang, H; Ye, C et al. (2017) Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601. Eur J Cancer Care (Engl) 26:|
|Bell, Erica Hlavin; Pugh, Stephanie L; McElroy, Joseph P et al. (2017) Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525. JAMA Oncol 3:784-792|
|Cohn, David E; Sill, Michael W; Walker, Joan L et al. (2017) Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 146:477-483|
|Papaioannou, Dimitrios; Nicolet, Deedra; Volinia, Stefano et al. (2017) Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. Haematologica 102:1391-1400|
Showing the most recent 10 out of 106 publications